TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of an Intervention of Urban Training in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomised Controlled Trial
Brief Summary: This project plans on a training intervention by using public spaces and urban walkable trails, adapted to each patient needs and capabilities. Primary objective is to assess 12 months effectiveness of the intervention with respect to: (primary outcome): physical activity level, and (secondary outcomes): COPD admissions, exercise capacity, body composition, quality of life, and mental health.


Options:
A: Arm Label: Urban training Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Urban training | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Urban training; Assigned to Arm(s): Urban training Intervention
B: Arm Label: Intervention--PACT Intensive Management; Type: EXPERIMENTAL; Interventions: Behavioral: PACT Intensive Management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: PACT Intensive Management; Assigned to Arm(s): Intervention--PACT Intensive Management
C: Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Behavioral: Case Management | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Case Management; Assigned to Arm(s): Case Management
D: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hypoalgesic Effect of TENS Modulation in Post-Cesarean Pain: A Clinical Trial Controlled and Randomized.
Brief Summary: The aim of the study was to evaluate the analgesic effect of transcutaneous electrical nerve stimulation High (100 Hz) and low (4 Hz) frequency in postpartum pain after cesarean section.


Options:
A: Arm Label: Narcotic counseling script; Type: EXPERIMENTAL; Interventions: Behavioral: Narcotic counseling script | Arm Label: Post-partum depression counseling script; Type: SHAM_COMPARATOR; Interventions: Behavioral: Post-partum depression counseling script | Intervention Type: BEHAVIORAL; Name: Narcotic counseling script; Assigned to Arm(s): Narcotic counseling script | Intervention Type: BEHAVIORAL; Name: Post-partum depression counseling script; Assigned to Arm(s): Post-partum depression counseling script
B: Arm Label: Binder; Type: EXPERIMENTAL; Interventions: Device: Elastic abdominal binder | Arm Label: No binder; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Elastic abdominal binder; Assigned to Arm(s): Binder
C: Arm Label: grupo TENS com frequência de 100 Hz; Type: EXPERIMENTAL; Interventions: Device: transcutaneous electrical nerve stimulation | Arm Label: grupo TENS com frequência de 4 Hz; Type: EXPERIMENTAL; Interventions: Device: transcutaneous electrical nerve stimulation | Arm Label: Placebo with TENS off; Type: PLACEBO_COMPARATOR; Interventions: Device: transcutaneous electrical nerve stimulation | Intervention Type: DEVICE; Name: transcutaneous electrical nerve stimulation; Assigned to Arm(s): Placebo with TENS off, grupo TENS com frequência de 100 Hz, grupo TENS com frequência de 4 Hz
D: Arm Label: Verum acupuncture; Type: EXPERIMENTAL; Interventions: Drug: Standard therapy, Device: Verum acupuncture | Arm Label: Placebo acupuncture; Type: PLACEBO_COMPARATOR; Interventions: Drug: Standard therapy, Other: Placebo acupuncture | Arm Label: Standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard therapy | Intervention Type: DRUG; Name: Standard therapy; Assigned to Arm(s): Placebo acupuncture, Standard therapy, Verum acupuncture | Intervention Type: DEVICE; Name: Verum acupuncture; Assigned to Arm(s): Verum acupuncture | Intervention Type: OTHER; Name: Placebo acupuncture; Assigned to Arm(s): Placebo acupuncture

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Which is the Best IVF/ICSI Protocol to be Used in Poor Responders Receiving Growth Hormone as an Adjuvant Treatment ? A Prospective Randomized Study
Brief Summary: in this study, we are trying to monitor the effect of the addition of growth hormone on the different down regulation protocols ( long, short, antagonist and microflare). The outcome will be primarily assessed by the clinical pregnancy rates.


Options:
A: Arm Label: The Long protocol; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Arm Label: The Short protocol; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Arm Label: The Antagonist protocol; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Arm Label: The Microflare protocol; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Intervention Type: DRUG; Name: Growth hormone (Norditropin, Novo nordisk); Assigned to Arm(s): The Antagonist protocol, The Long protocol, The Microflare protocol, The Short protocol
B: Arm Label: Long + Growth hormone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Growth hormone | Arm Label: Long protocol only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Growth hormone; Assigned to Arm(s): Long + Growth hormone
C: Arm Label: Antagonist and Growth hormone; Type: EXPERIMENTAL; Interventions: Drug: Growth Hormone | Arm Label: Antagonist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Growth Hormone; Assigned to Arm(s): Antagonist and Growth hormone
D: Arm Label: Microflare and growth hormone; Type: EXPERIMENTAL; Interventions: Drug: Growth hormone (Norditropin, Novo nordisk) | Arm Label: Microflare protocol alone; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Growth hormone (Norditropin, Novo nordisk); Assigned to Arm(s): Microflare and growth hormone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting
Brief Summary: PONV (Postoperative nausea and vomiting) is one of most common complications after general anesthesia. Female sex, history of PONV, motion sickness, nonsmoker status, use of volatile agents, duration of anesthesia, opioid administration and laparoscopic surgery are known as risk factors for developing PONV. In consequence, patients undergoing laparoscopic gynecologic surgery are at high risk for developing PONV. Most of these patients use fentanyl based IV-PCA. And it also causes PONV.

So, we should prevent PONV in these patients by using multimodal or combination therapy.

Aprepitant is a NK1 receptor antagonist.And it is used to prevent chemotherapy induced nausea and vomiting. Many studies using aprepitant to prevent PONV are in progress.

In this study, we investigate the effect of combining aprepitant with ondansetron in high-risk patients for PONV.


Options:
A: Arm Label: Aprepitant group; Type: EXPERIMENTAL; Interventions: Drug: Aprepitant | Arm Label: placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aprepitant; Assigned to Arm(s): Aprepitant group | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo group
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: GW679769 (casopitant) | Intervention Type: DRUG; Name: GW679769 (casopitant); Assigned to Arm(s): Arm 1
C: Intervention Type: DRUG; Name: intravenous ondansetron; Assigned to Arm(s): N/A
D: Arm Label: Dexamethasone group; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous dexamethasone | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Homologated placebo. | Intervention Type: DRUG; Name: intravenous dexamethasone; Assigned to Arm(s): Dexamethasone group | Intervention Type: DRUG; Name: Homologated placebo.; Assigned to Arm(s): Placebo group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk
Brief Summary: The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with Type 2 diabetes mellitus (T2DM) and to compare outcomes against placebo, on a background of standard of care.


Options:
A: Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo
B: Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin
C: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dapagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Empagliflozin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Empagliflozin | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Renal Denervation in Improving Outcomes of Catheter Ablation in Patients With Atrial Fibrillation and Arterial Hypertension
Brief Summary: The purpose of this study is the comparative evaluation of systolic blood pressure (SBP) lowering, atrial fibrillation (AF) recurrence and clinical data in patients with paroxysmal/persistent AF and resistant/non-resistant hypertension, undergoing AF ablation alone or combined with percutaneous renal denervation.


Options:
A: Arm Label: PV isolation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: PV isolation+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PV isolation+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): PV isolation | Intervention Type: PROCEDURE; Name: PV isolation+renal denervation; Assigned to Arm(s): PV isolation+renal denervation
B: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: Renal sympathetic denervation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Renal sympathetic denervation; Assigned to Arm(s): Renal sympathetic denervation
C: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Renal Denervation | Intervention Type: DEVICE; Name: Renal Denervation; Assigned to Arm(s): Renal Denervation
D: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Renal Denervation in Improving Outcomes of Catheter Ablation in Patients With Atrial Fibrillation and Arterial Hypertension
Brief Summary: The purpose of this study is the comparative evaluation of systolic blood pressure (SBP) lowering, atrial fibrillation (AF) recurrence and clinical data in patients with paroxysmal/persistent AF and resistant/non-resistant hypertension, undergoing AF ablation alone or combined with percutaneous renal denervation.


Options:
A: Intervention Type: DEVICE; Name: Symplicty(TM) Catheter System; Assigned to Arm(s): N/A
B: Arm Label: renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: renal sympathetic denervation, Drug: drug, Procedure: Direct-Current Cardioversion | Arm Label: drug therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: drug | Intervention Type: PROCEDURE; Name: renal sympathetic denervation; Assigned to Arm(s): renal sympathetic denervation | Intervention Type: DRUG; Name: drug; Assigned to Arm(s): drug therapy, renal sympathetic denervation | Intervention Type: PROCEDURE; Name: Direct-Current Cardioversion; Assigned to Arm(s): renal sympathetic denervation
C: Arm Label: PV isolation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: PV isolation+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PV isolation+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): PV isolation | Intervention Type: PROCEDURE; Name: PV isolation+renal denervation; Assigned to Arm(s): PV isolation+renal denervation
D: Arm Label: Renal denervation; Type: N/A; Interventions: Device: Renal denervation using Symplicity Catheter system | Intervention Type: DEVICE; Name: Renal denervation using Symplicity Catheter system; Assigned to Arm(s): Renal denervation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles - A Quality Improvement Theragnostic Stewardship Project
Brief Summary: Would rapid identification of bacteria and rapid detection of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) (using an FDA-cleared assay) in positive blood culture bottles improve patient care at Mayo Clinic Rochester (or just lead to increased cost)?


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: detection of microbial DNA in blood by blood culture | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Detection of microbial DNA in blood by SeptiFast® | Intervention Type: OTHER; Name: Detection of microbial DNA in blood by SeptiFast®; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: detection of microbial DNA in blood by blood culture; Assigned to Arm(s): 2
B: Arm Label: Control; Type: EXPERIMENTAL; Interventions: Other: Bacterial culture, Other: Susceptibility testing | Arm Label: FilmArray test; Type: EXPERIMENTAL; Interventions: Device: FilmArray testing, Other: Bacterial culture, Other: Susceptibility testing | Arm Label: FilmArray plus antimicrobial stewardship; Type: EXPERIMENTAL; Interventions: Device: FilmArray testing, Behavioral: Antimicrobial Stewardship, Other: Bacterial culture, Other: Susceptibility testing | Intervention Type: DEVICE; Name: FilmArray testing; Assigned to Arm(s): FilmArray plus antimicrobial stewardship, FilmArray test | Intervention Type: BEHAVIORAL; Name: Antimicrobial Stewardship; Assigned to Arm(s): FilmArray plus antimicrobial stewardship | Intervention Type: OTHER; Name: Bacterial culture; Assigned to Arm(s): Control, FilmArray plus antimicrobial stewardship, FilmArray test | Intervention Type: OTHER; Name: Susceptibility testing; Assigned to Arm(s): Control, FilmArray plus antimicrobial stewardship, FilmArray test
C: Arm Label: betaLACTA® result given to physician; Type: EXPERIMENTAL; Interventions: Device: betaLACTA® rapid diagnostic test | Arm Label: betaLACTA® result NOT given to physician; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: betaLACTA® rapid diagnostic test; Assigned to Arm(s): betaLACTA® result given to physician
D: Arm Label: Xpert MRSA/SA SSTI; Type: EXPERIMENTAL; Interventions: Device: Xpert MRSA/SA SSTI | Arm Label: Standard culture; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Standard culture | Intervention Type: DEVICE; Name: Xpert MRSA/SA SSTI; Assigned to Arm(s): Xpert MRSA/SA SSTI | Intervention Type: DIAGNOSTIC_TEST; Name: Standard culture; Assigned to Arm(s): Standard culture

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The aim of this study is to verify that the frequency of pancreatic fistula (ISGPF grade B and C) in horizontal mattress suture are lower than in interrupted suture during pancreaticojejunostomy in pancreatoduodenectomy by randomized clinical trial.


Options:
A: Arm Label: horizontal mattress; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy with horizontal mattress suture | Arm Label: interrupted suture; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy with interrupted suture | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy with horizontal mattress suture; Assigned to Arm(s): horizontal mattress | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy with interrupted suture; Assigned to Arm(s): interrupted suture
B: Arm Label: one-layer duct-to-mucosa anastomosis; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy | Arm Label: two-layer duct-to-mucosa anastomosis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy; Assigned to Arm(s): one-layer duct-to-mucosa anastomosis, two-layer duct-to-mucosa anastomosis
C: Arm Label: Duct to mucosa PJ group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Duct to mucosa PJ group | Arm Label: Invagination PJ group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Invagination PJ group | Intervention Type: PROCEDURE; Name: Duct to mucosa PJ group; Assigned to Arm(s): Duct to mucosa PJ group | Intervention Type: PROCEDURE; Name: Invagination PJ group; Assigned to Arm(s): Invagination PJ group
D: Arm Label: Mucosa-to-jejunal mucosa technique of pancreaticojejunosto; Type: EXPERIMENTAL; Interventions: Procedure: pancreaticojejunostomy | Intervention Type: PROCEDURE; Name: pancreaticojejunostomy; Assigned to Arm(s): Mucosa-to-jejunal mucosa technique of pancreaticojejunosto

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Randomized, Single-Dose, Open-Label Crossover Study to Investigate the Effect of Food on the Relative Bioavailability of 2 Fixed-Dose Combinations of Lumacaftor and Ivacaftor Tablet Formulations in Healthy Adult Subjects
Brief Summary: This study is designed to investigate the effect of food on the relative bioavailability of 2 different strengths of fixed-dose combinations of lumacaftor and ivacaftor tablet formulations.


Options:
A: Arm Label: Part A; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Arm Label: Part B; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Intervention Type: DRUG; Name: lumacaftor; Assigned to Arm(s): Part A, Part B | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): Part A, Part B
B: Arm Label: GLPG2222 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 150 mg q.d. | Arm Label: GLPG2222 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: GLPG2222 300 mg q.d. | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GLPG2222 150 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 1 | Intervention Type: DRUG; Name: GLPG2222 300 mg q.d.; Assigned to Arm(s): GLPG2222 Dose 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Miglustat; Type: ACTIVE_COMPARATOR; Interventions: Drug: Miglustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Miglustat; Assigned to Arm(s): Miglustat | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Group 1 - 50 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 2 - 100 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 3 - 200 mg; Type: EXPERIMENTAL; Interventions: Drug: N91115 | Arm Label: Group 4 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: N91115 | Intervention Type: DRUG; Name: N91115; Assigned to Arm(s): Group 1 - 50 mg, Group 2 - 100 mg, Group 3 - 200 mg, Group 4 - Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1, Randomized, Single-Dose, Open-Label Crossover Study to Investigate the Effect of Food on the Relative Bioavailability of 2 Fixed-Dose Combinations of Lumacaftor and Ivacaftor Tablet Formulations in Healthy Adult Subjects
Brief Summary: This study is designed to investigate the effect of food on the relative bioavailability of 2 different strengths of fixed-dose combinations of lumacaftor and ivacaftor tablet formulations.


Options:
A: Arm Label: Part A; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Arm Label: Part B; Type: EXPERIMENTAL; Interventions: Drug: lumacaftor, Drug: ivacaftor | Intervention Type: DRUG; Name: lumacaftor; Assigned to Arm(s): Part A, Part B | Intervention Type: DRUG; Name: ivacaftor; Assigned to Arm(s): Part A, Part B
B: Arm Label: Part A: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM, Drug: IVA | Arm Label: Part B: LUM/IVA; Type: EXPERIMENTAL; Interventions: Drug: LUM, Drug: IVA | Intervention Type: DRUG; Name: LUM; Assigned to Arm(s): Part A: LUM/IVA, Part B: LUM/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): Part A: LUM/IVA, Part B: LUM/IVA
C: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA
D: Arm Label: PTC124 PO; Type: EXPERIMENTAL; Interventions: Drug: PTC124 | Intervention Type: DRUG; Name: PTC124; Assigned to Arm(s): PTC124 PO

Answer: A